CClinicalTrials.gg
CompletedNCT01854541VMRTPUpdated Apr 10, 2015

Visual Management for the Radiotherapy Process

An observational study in Cancer, sponsored by Maastricht Radiation Oncology. Completed at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2015-04-10.

Sponsored by Maastricht Radiation Oncology · Observational

Study type
Observational
Model
Cohort
Enrollment
10,000
Sex
All
01

Study summary

The Visual Management for Radiotherapy Practice (VMRTP) aims to analyze, predict, visualize and shorten the waiting times for radiotherapy patients. The hypothesis is that this can be done by the introduction of models that can predict a patient being at risk for waiting too long as well as visual management tools that visualize the radiotherapy process.

Read the detailed description

In a retrospective cohort of radiotherapy patients, time stamps of various steps in the radiotherapy process (diagnosis, multi-disciplinary board, referral, intake, simulation, treatment planning, quality control, first fraction of radiotherapy) will be collected. These will be combined with patient, tumor and patient-process (e.g. referring physician, treating physician, busy-at-the-time, referring hospital) related features. Based on these a predictive model will be learned that can estimate the probability at various stages of the process that the patient waits too long. Visual management will be developed that can visualize the predicted waiting time.

Process interventions aimed at reducing waiting times will be tested prospectively.

02

Conditions studied

  • Cancer

Keywords

  • Cancer
  • Radiotherapy
03

In context

Lead sponsor

Maastricht Radiation Oncology is the lead sponsor of 104 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients treated with radiotherapy

Inclusion criteria

Patients receiving radiotherapy

Exclusion criteria

Exclusion Criteria:

Patients not receiving radiotherapy

05

Study design

Observational model
Cohort
Enrollment
10,000 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Radiotherapy

    All patients receiving radiotherapy

06

What researchers measure

Primary outcomes

  1. referral and first day of radiotherapy

    Waiting time between referral and first day of radiotherapy

    Time frame: 3 months

Secondary outcomes

  1. Diagnosis and first day of radiotherapy

    Waiting time between diagnosis and first day of radiotherapy

    Time frame: 3 months

  2. multi-disciplinary board and first day of radiotherapy

    Waiting time between multi-disciplinary board and first day of radiotherapy

    Time frame: 3 months

  3. intake and first day of radiotherapy

    Waiting time between intake and first day of radiotherapy

    Time frame: 3 months

  4. simulation and first day of radiotherapy

    Waiting time between simulation and first day of radiotherapy

    Time frame: 3 months

07

Study locations

1 site
  • MAASTRO clinic
    Maastricht, 6229 ET, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01854541
Lead sponsor
Maastricht Radiation Oncology
Collaborators
Maastro Clinic, The Netherlands
Responsible party
Sponsor
First posted
May 15, 2013
Start date
Mar 2013
Primary completion
Jan 2015
Completion
Jan 2015
Last update
Apr 10, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion